Michelle F Devine1,2,3,4, John C Feemster1,5, Elizabeth A Lieske5, Stuart J McCarter1,2,3,5, David J Sandness1,5, Tyler Steele5, Paul C Timm1,5, Jay Mandrekar3,6, Bradley F Boeve1,3, Michael H Silber1,3, Divyanshu Dubey3,7, Andrew McKeon3,7, Erik K St Louis1,2,3,5,8. 1. Mayo Clinic Center for Sleep Medicine, Mayo Clinic and Foundation, Rochester, MN, USA. 2. Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Mayo Clinic and Foundation, Rochester, MN, USA. 3. Department of Neurology, Mayo Clinic and Foundation, Rochester, MN, USA. 4. Olmsted Medical Center, Rochester, MN, USA. 5. Mayo Sleep Behavior and Neurophysiology Research Laboratory, Mayo Clinic and Foundation, Rochester, MN, USA. 6. Department of Biostatistics, Mayo Clinic and Foundation, Rochester, MN, USA. 7. Department of Pathology/Laboratory Medicine, Mayo Clinic and Foundation, Rochester, MN, USA. 8. Mayo Clinic Health System Southwest Wisconsin-La Crosse, Mayo Clinic and Foundation, Rochester, MN, USA.
Abstract
STUDY OBJECTIVES: Rapid eye movement (REM) sleep behavior disorder (RBD) and other sleep disturbances are frequent in leucine-rich, glioma inactivated protein 1-IgG (LGI1) and contactin-associated protein 2-IgG (CASPR2) autoimmunity, yet polysomnographic analyses of these disorders remain limited. We aimed to characterize clinical presentations and analyze polysomnographic manifestations, especially quantitative REM sleep without atonia (RSWA) in LGI1/CASPR2-IgG seropositive (LGI/CASPR2+) patients. METHODS: We retrospectively analyzed clinical and polysomnographic features and quantitative RSWA between LGI1+/CASPR2+ patients and age-sex matched controls. Groups were compared with Wilcoxon rank-sum and chi-square tests. Combined submentalis and anterior tibialis (SM + AT) RSWA was the primary outcome. RESULTS: Among 11 (LGI1+, n = 9; CASPR2+, n = 2) patients, Morvan syndrome sleep features were present in seven (63.6%) LGI1+/CASPR2+ patients, with simultaneous insomnia and dream enactment behavior (DEB) in three (27.3%), and the most common presenting sleep disturbances were DEB (n = 5), insomnia (n = 5), and sleep apnea (n = 8; median apnea-hypopnea index = 15/hour). Median Epworth Sleepiness Scale was nine (range 3-24; n = 10), with hypersomnia in four (36.4%). LGI1+/CASPR2+ patients had increased N1 sleep (p = .02), decreased REM sleep (p = .001), and higher levels of SM + AT any RSWA (p < .001). Eight of nine (89%) LGI1+ exceeded RBD RSWA thresholds (DEB, n = 5; isolated RSWA, n = 3). RSWA was greater in AT than SM. All 10 LGI1+/CASPR2+ patients treated with immunotherapy benefitted, and 5/10 had improved sleep disturbances. CONCLUSIONS: LGI1/CASPR2-IgG autoimmunity is associated with prominent dream enactment, insomnia, RSWA, sleep apnea, and shallower sleep. Polysomnography provides objective disease markers in LGI1+/CASPR2+ autoimmunity and immunotherapy may benefit associated sleep disturbances.
STUDY OBJECTIVES: Rapid eye movement (REM) sleep behavior disorder (RBD) and other sleep disturbances are frequent in leucine-rich, glioma inactivated protein 1-IgG (LGI1) and contactin-associated protein 2-IgG (CASPR2) autoimmunity, yet polysomnographic analyses of these disorders remain limited. We aimed to characterize clinical presentations and analyze polysomnographic manifestations, especially quantitative REM sleep without atonia (RSWA) in LGI1/CASPR2-IgG seropositive (LGI/CASPR2+) patients. METHODS: We retrospectively analyzed clinical and polysomnographic features and quantitative RSWA between LGI1+/CASPR2+ patients and age-sex matched controls. Groups were compared with Wilcoxon rank-sum and chi-square tests. Combined submentalis and anterior tibialis (SM + AT) RSWA was the primary outcome. RESULTS: Among 11 (LGI1+, n = 9; CASPR2+, n = 2) patients, Morvan syndrome sleep features were present in seven (63.6%) LGI1+/CASPR2+ patients, with simultaneous insomnia and dream enactment behavior (DEB) in three (27.3%), and the most common presenting sleep disturbances were DEB (n = 5), insomnia (n = 5), and sleep apnea (n = 8; median apnea-hypopnea index = 15/hour). Median Epworth Sleepiness Scale was nine (range 3-24; n = 10), with hypersomnia in four (36.4%). LGI1+/CASPR2+ patients had increased N1 sleep (p = .02), decreased REM sleep (p = .001), and higher levels of SM + AT any RSWA (p < .001). Eight of nine (89%) LGI1+ exceeded RBD RSWA thresholds (DEB, n = 5; isolated RSWA, n = 3). RSWA was greater in AT than SM. All 10 LGI1+/CASPR2+ patients treated with immunotherapy benefitted, and 5/10 had improved sleep disturbances. CONCLUSIONS: LGI1/CASPR2-IgG autoimmunity is associated with prominent dream enactment, insomnia, RSWA, sleep apnea, and shallower sleep. Polysomnography provides objective disease markers in LGI1+/CASPR2+ autoimmunity and immunotherapy may benefit associated sleep disturbances.
Authors: Stuart J McCarter; David J Sandness; Allison R McCarter; John C Feemster; Luke N Teigen; Paul C Timm; Bradley F Boeve; Michael H Silber; Erik K St Louis Journal: Neurology Date: 2019-08-16 Impact factor: 9.910
Authors: Ronald B Postuma; Jean-Francois Gagnon; Maria Tuineaig; Josie-Anne Bertrand; Veronique Latreille; Catherine Desjardins; Jacques Y Montplaisir Journal: Sleep Date: 2013-11-01 Impact factor: 5.849
Authors: Stuart J McCarter; Erik K St Louis; David J Sandness; Ethan J Duwell; Paul C Timm; Bradley F Boeve; Michael H Silber Journal: Sleep Med Date: 2016-05-11 Impact factor: 3.492
Authors: Stuart J McCarter; Maja Tippmann-Peikert; David J Sandness; Eoin P Flanagan; Kejal Kantarci; Bradley F Boeve; Michael H Silber; Erik K St Louis Journal: Sleep Med Date: 2015-09-14 Impact factor: 3.492
Authors: Christopher J Klein; Vanda A Lennon; Paula A Aston; Andrew McKeon; Orna O'Toole; Amy Quek; Sean J Pittock Journal: JAMA Neurol Date: 2013-02 Impact factor: 18.302
Authors: Stuart J McCarter; John C Feemster; Grace M Tabatabai; David J Sandness; Paul C Timm; Allison R McCarter; Heather N Talley; Mithri R Junna; Rodolfo Savica; Wolfgang Singer; Elizabeth A Coon; Eduardo E Benarroch; Keith A Josephs; Bradley F Boeve; Michael H Silber; Erik K St Louis Journal: Ann Neurol Date: 2019-12 Impact factor: 10.422
Authors: Bethan Lang; Mateusz Makuch; Teresa Moloney; Inga Dettmann; Swantje Mindorf; Christian Probst; Winfried Stoecker; Camilla Buckley; Charles R Newton; M Isabel Leite; Paul Maddison; Lars Komorowski; Jane Adcock; Angela Vincent; Patrick Waters; Sarosh R Irani Journal: J Neurol Neurosurg Psychiatry Date: 2017-01-23 Impact factor: 10.154